Diagnocure CUR Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diagnocure CUR

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Claude Robitaille who started this subject	10/29/2001 1:34:26 PM
From: Mr. L. Neufeldt	Read Replies (1) of 132

With Abbott buying out Vysis for $355 million for their diagnostic capabilities, does that make Diagnocure a potential buyout target. uPM3 results should be out within two weeks and the results are anticipated as being very positive. At $0.90/share, Diagnocure is severely undervalued with potential and anticipated revenue of $30 million by 2004. Or if you subscribe to them being one year off their target then by 2005. Vysis sales were just beginning to ramp up at about $22 million. Diagnocure's future revenue stream seems to have potential to head the same path. Prostates cancer test market is anticipated at being $1 to $2.5 Billion. Obviously Abbott wants to control this aspect of the market with their PSA test. What does that make Diagnocure really worth??? Not $0.90/share!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next